1. Generics Bulletin
  2. >>Leadership

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Viatris And Teva Both Appear Increasingly Interested In Branded Businesses

 
• By Chloe Kent

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Magnifying glass placed on the table with group of paper human dolls, and only one in the focus

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies. This ranged from small biotechs like women’s health company Mithra – with new CEO David Solomon signaling the potential sale of its generics business just one month into the role – to major industry players like Viatris and Teva.

Viatris has long expressed ambitions of moving into more innovative and high-growth business areas as part of its long-term business plan. (Also see "A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions" - Generics Bulletin, 21 December, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin